Today Kedrion Biopharma announced the nationwide commercial availability of QIVIGY, its FDA‑approved 10% Intravenous ...

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year GrowthFY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% ...

“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...

Gammagard Liquid ERC is a ready-to-use, low IgA immunoglobulin therapy that can be administered intravenously or subcutaneously. Gammagard Liquid ® ERC (immune globulin infusion [human] 10% solution) ...

− GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Now Available by Prescription for Intravenous or Subcutaneous Use in People Aged ...

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 − GAMMAGARD LIQUID ERC [immune globulin ...

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to the 1950s, IVIG is currently ...

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to the 1950s, IVIG is currently ...

Dedicated Devices for HYQVIA [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] Reduce the Number of Steps and Ancillary Supplies Compared to a Pooling Bag When Preparing the ...